Qian Zhu

Qian Zhu

Auto-generated profile, based on publicly available information

Qian Zhu

Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QZQian Zhu
Qian Zhu
LCLingli Cui
Lingli Cui
XLXinyue Li
Xinyue Li
QLQipei Li
Qipei Li
YWYun Wang
Yun Wang
Purpose: The number of young women undergoing painless gastroscopy is rising annually. However, the lack of studies on the effective doses of propofol sedation for young, underweight women, presents a clinical challenge. Our study aimed to determine and compare the effective doses of propofol required for successful gastroscope insertion in normal-weight and underweight young women. Patients and Methods: Chinese women aged 18– 35 years who were of normal weight (18.5 ≤ body mass index (BMI) < 25 kg/m²) or underweight (BMI < 18.5 kg/m²) and were undergoing painless gastroscopy were included. The initial induction dose of propofol was 2.0 mg/kg, and subsequent doses were adjusted using the modified Dixon’s up-and-down method (step size: 0.1 mg/kg). The 50% and 95% effective dose of propofol (ED50 and ED95), defined as the doses required for successful gastroscope insertion in 50% and 95% of patients, respectively, were determined using the modified Dixon’s up-and-down method and isotonic regression analysis. All adverse events were documented. Results: Thirty patients were included in each group. The modified Dixon’s up-and-down method was used, and the ED50 of propofol was found to be significantly higher in patients in the underweight group (2.72 ± 0.23 mg/kg) than those in the normal-weight group (2.03 ± 0.13 mg/kg) (P < 0.001). The ED50 and ED95 in the normal-weight group extrapolated using isotonic regression analysis were 2.00 (83% confidence interval [CI], 1.900– 2.100) mg/kg and 2.30 (83% CI, 2.300– 2.400) mg/kg, respectively. In the underweight group, these values increased to 2.80 (83% CI, 2.700– 2.900) mg/kg and 3.00 (83% CI, 3.000– 3.100) mg/kg, respectively. The nonoverlapping CIs indicated significant differences between patients in the normal-weight and underweight groups. Conclusion: Young, healthy, underweight women require higher effective doses of propofol for deep sedation for successful gastroscope insertion compared with young, healthy, normal-weight women.

1 January 2026 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
QZQian Zhu
Qian Zhu
PHPei-Pei Hao
Pei-Pei Hao
LCLing-Li Cui
Ling-Li Cui
FLFu-Kun Liu
Fu-Kun Liu
Fu-Shan XueFu-Shan Xue
Fu-Shan Xue
Purpose: Patients undergoing painless gastrointestinal endoscopy (GIE) typically receive propofol-based sedation. However, the exact dose of propofol when combined with low-dose dexmedetomidine for this procedure remains unclear. The objective of this study was to determine and compare the median effective doses (ED50, the doses required for successful gastroscope insertion in 50% of the subjects) of propofol when used with low-dose dexmedetomidine (0.3 μg/kg) premedication versus propofol alone during painless GIE. Patients and Methods: Adult outpatients aged 18 to 65 years scheduled for GIE were enrolled. Participants were randomized to receive either 0.9% saline (Group S) or 0.3 μg/kg of dexmedetomidine (Group D) intravenously over 5 min before induction with propofol. Using modified Dixon’s up-and-down method (MDUDM), the initial induction dose of propofol was 1.5 mg/kg, adjusted in a step size of 0.1 mg/kg. ED50 of propofol required for successful endoscope insertion was calculated by averaging the midpoints of all sequential crossovers. Using isotonic regression analysis, ED50 and ED95 (the effective doses required for successful gastroscope insertion in 95% of the subjects) were then extrapolated. All adverse events during painless GIE were recorded. Results: Thirty patients were enrolled per group. Using MDUDM, the ED50 of propofol for successful gastroscope insertion was significantly lower in Group D (1.48 ± 0.10 mg/kg) than in Group S (1.82 ± 0.16 mg/kg; P < 0.001). The ED50 and ED95 of propofol were extrapolated to 1.80 mg/kg (83% confidence interval [CI], 1.649– 1.882) and 2.10 mg/kg (83% CI, 2.081– 2.124) for Group S, respectively, using isotonic regression analysis. These values were significantly lower in Group D, at 1.40 mg/kg (83% CI, 1.297– 1.452) and 1.70 mg/kg (83% CI, 1.667– 1.753). Conclusion: Premedication with low-dose dexmedetomidine (0.3 μg/kg) significantly reduces the median effective doses of propofol required for successful gastroscope insertion during painless GIE.

1 May 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LCLing-Li Cui
Ling-Li Cui
LZLiang Zhang
Liang Zhang
SLShen Liu
Shen Liu
QZQian Zhu
Qian Zhu
Fu-Shan XueFu-Shan Xue
Fu-Shan Xue
Purpose: To determine the effects of intraoperative dexmedetomidine (DEX) administration on postoperative ischaemia/reperfusion injury (HIRI) and clinical outcomes of patients undergoing the laparoscopic living donor hepatectomy (LLDH). Patients and Methods: Fifty-five patients who underwent the LLDH were randomly assigned to the DEX or control group. The DEX group received an intravenous infusion of DEX with an bolus dose of 1 μg/kg for 15 min before anaesthesia induction, followed by a continuous infusion at a rate of 0.4 μg/kg/h until the portal branch was disconnected. The control group was given an intravenous infusion of 0.9% saline at same volume and rate. The primary outcome was peak serum aspartate aminotransferase (AST) level during the first 72 h postoperatively. The secondary outcomes included other variables of postoperative liver and kidney function, intraoperative hemodynamic changes, postoperative recovery outcomes and the occurrence of complications. Results: The peak serum AST level during the first 72 h postoperatively was not significantly different between groups (DEX vs control: 288 [194– 466] vs 324 [194– 437] IU/L; difference, − 1.2 IU/L; 95% CI, − 86.9 to 88.0; P=0.973). The intraoperative mean artery pressure was not significantly different, but intraoperative heart rate was significantly decreased in the DEX group. There were no significant differences between groups in other secondary outcomes. Conclusion: This study demonstrates that intraoperative DEX administration at the studied dosage regimens cannot attenuate postoperative HIRI and does not improve clinical outcomes in patients undergoing the LLDH. Clinical Trial Registration: www.chictr.org.cn, ChiCTR2000040629.

1 May 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
LCLingli Cui
Lingli Cui
YZYichen Zhu
Yichen Zhu
SLShen Liu
Shen Liu
LZLiang Zhang
Liang Zhang
QZQian Zhu
Qian Zhu
DMDanxu Ma
Danxu Ma
Introduction: Laparoscopic donor nephrectomy (LDN) is the standard procedure for donor nephrectomy for living kidney transplantation. Compared with traditional open surgery, the laparoscopic techniques have been developed to significantly reduce postoperative pain and accelerate postoperative recovery; however, most donors still experience more than moderate pain after surgery. Ensuring maximum perioperative safety and postoperative pain control for donors remains a top priority for LDN. Our group reported a novel blockade technique that allows local anesthetic to be injected directly to reach the low thoracic paravertebral space under direct laparoscopic observation via the arcuate ligament to achieve somatic and visceral pain analgesia; this technique has been successfully applied to patients undergoing retroperitoneal laparoscopic nephrectomy. We hypothesized that compared with the transversus abdominis plane (TAP) block, low thoracic paravertebral block (TPVB) via the arcuate ligament under direct vision would reduce the consumption of postoperative opioids and improve the quality of postoperative recovery of donors after LDN. Methods/Analysis: This study is a prospective blind, randomized, controlled clinical trial with a concealed allocation of donors scheduled to undergo elective LDN 1:1 to receive either a low TPVB via the arcuate ligament under direct vision or a TAP block. This study will recruit a total of 82 living kidney donors. The primary outcome is the 15-item recovery quality scale (QoR-15) score at 24 hours after surgery. Ethics and Dissemination: This trial was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University. This trial study protocol was approved on 30 November 2024. The trial started recruiting patients after being registered on the Chinese Clinical Trial Registry. Trial Registration Number: ChiCTR2400094612.